

SECURITIES AND EXCHANGE COMMISSION

FORM N-MFP

Monthly schedule of portfolio holdings of money market funds

Filing Date: **2011-11-07** | Period of Report: **2011-10-31**
SEC Accession No. **0001145549-11-011752**

(HTML Version on secdatabase.com)

FILER

T. Rowe Price Fixed Income Series, Inc.

CIK: **920467** | IRS No.: **000000000** | State of Incorporation: **MD** | Fiscal Year End: **1231**
Type: **N-MFP** | Act: **33** | File No.: **811-07153** | Film No.: **111184188**

Mailing Address
*100 EAST PRATT STREET
BALTIMORE MD 21202*

Business Address
*100 EAST PRATT STREET
BALTIMORE MD 21202
410-345-2000*

UNITED STATES SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

FORM N-MFP

OMB APPROVAL

OMB Number: 3235-0657
Expires: 05/31/2013
Estimated average burden
hours per response 10.9

MONTHLY SCHEDULE OF PORTFOLIO HOLDINGS OF
MONEY MARKET FUNDS

1. Identity Information

Is this an electronic copy of an official filing submitted in paper format? No

Report date: October 31, 2011

CIK Number of Registrant: 0000920467

EDGAR Series Identifier: S000002130

Total number of share classes in the series: 1

Do you anticipate this will be the fund's final filing on Form N-MFP? No

If this is not a final filing, has the fund acquired or merged with another fund since the last filing? No

Part 1: Information about the Fund

A. Series-Level Information

Item 1. Securities Act File Number: 033-52749

Item 2. Investment Adviser

Investment Adviser	SEC file number of investment adviser
T. Rowe Price Associates, Inc.	801-856

Item 4. Independent Public Accountant

Name	City, State
PricewaterhouseCoopers LLP	Baltimore, MD

Item 5. Administrator. If a fund has one or more administrators, disclose the name of each administrator

Administrator
None

Item 6. Transfer Agent

Transfer Agent	CIK number	SEC file number of transfer agent
T. Rowe Price Services, Inc.	0000703220	84-1079

Item 7. Master-Feeder Funds. Is this a feeder fund? No

Item 8. Master-Feeder Funds. Is this a master fund? No

Item 9. Is this series primarily used to fund insurance company separate accounts? Yes

Item 10. Category. Indicate the category that most closely identifies the money market fund: Prime

Item 11. Dollar weighted average portfolio maturity: 51 days

Item 12. Dollar weighted average life maturity. Calculate the dollar weighted average portfolio maturity without reference to the exceptions in rule 2a-7(d) regarding interest rate readjustments: 77 days

Item 13. Total value of portfolio securities at amortized cost, to the nearest cent: \$28,520,865.58

Item 14. Total value of other assets, to the nearest cent: \$85,072.38

Item 15. Total value of liabilities, to the nearest cent: \$82,837.85

Item 16. Net assets of the series, to the nearest cent: \$28,523,100.11

Item 17. 7-day gross yield: 0.27%

Item 18. Shallow Price of the Series. Net asset value per share most recent calculated using available market quotations (or an appropriate substitute that reflects current market conditions), to the nearest hundredth of a cent:

Net Asset Value per Share	Date Calculated
---------------------------	-----------------

Including capital support agreement	\$1.0008	2011-10-31
Excluding capital support agreement	\$1.0008	2011-10-31

B. Class-Level Information.

Item 19. EDGAR Class Identifier: [C000005522](#)

Item 20. Minimum Initial Investment: [\\$5,000.00](#)

Item 21. Net assets of the Class, to the nearest cent: [\\$28,523,100.11](#)

Item 22. Net asset value per share for purposes of distributions, redemptions, and repurchase, to the nearest cent: [\\$1.00](#)

Item 23. Net shareholder flow activity for the month ended: [\\$1,749,704.40](#)

Gross subscriptions for the month ended(including dividend reinvestments):	\$3,098,883.67
Gross redemptions for the month ended:	\$1,349,179.27

Item 24. 7-day net yield: [0.00%](#)

Item 25. Shadow Price of Each Class. Net asset value per share most recent calculated using available market quotations (or an appropriate substitute that reflects current market conditions)

	Net Asset Value per Share	Date Calculated
Including the value of any capital support agreement:	\$1.0008	2011-10-31
Excluding the value of any capital support agreement:	\$1.0008	2011-10-31

Part 2 - Schedule of Portfolio Securities

Security

Item 26. The name of the issuer: [American Honda Finance](#)

Item 27. The title of the issue (including coupon or yield): [American Honda Finance 0.319000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [02666QH97](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Instrument](#)

Brief description: (optional): [Taxable Interest Bearing Bond](#)

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$400,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$400,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.40%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$400,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$400,000.00**

Security

Item 26. The name of the issuer: **ASB Finance**

Item 27. The title of the issue (including coupon or yield): **ASB Finance 0.436000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **0020P5CC1**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Financial Company Commercial Paper**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-12-23**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-12-23**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$300,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$299,996.97**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.05%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$300,018.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$300,018.00**

Security

Item 26. The name of the issuer: **Australia & New Zealand Banking**

Item 27. The title of the issue (including coupon or yield): **Australia & New Zealand Banking 0.320000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **05253AB74**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Financial Company Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-02-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-02-07](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$320,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$319,721.24](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.12%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$319,798.50](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$319,798.50](#)

Security

Item 26. The name of the issuer: [Bank of Tokyo-Mitsubishi](#)

Item 27. The title of the issue (including coupon or yield): [Bank of Tokyo-Mitsubishi 0.350000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [06538DV30](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Certificate of Deposit](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-20](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-20](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$200,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$200,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.70%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$199,977.50**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$199,977.50**

Security

Item 26. The name of the issuer: **Bank of Tokyo-Mitsubishi**

Item 27. The title of the issue (including coupon or yield): **Bank of Tokyo-Mitsubishi 0.280000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **06538DZN2**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Certificate of Deposit**
Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-16**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-16**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$285,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$285,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.00%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$285,007.58**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$285,007.58**

Security

Item 26. The name of the issuer: **Baptist Memorial Health Care**

Item 27. The title of the issue (including coupon or yield): **Baptist Memorial Health Care 0.230000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [06684WAT6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-08](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-08](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$250,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$250,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$250,000.00](#)

Security

Item 26. The name of the issuer: [Baptist Memorial Health Care](#)

Item 27. The title of the issue (including coupon or yield): [Baptist Memorial Health Care 0.250000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [06684WAW9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-14](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-14](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$250,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$250,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$250,000.00](#)

Security

Item 26. The name of the issuer: [California HFA](#)

Item 27. The title of the issue (including coupon or yield): [California HFA 0.110000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [13033FK74](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CA HFFA - California	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$500,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$500,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.75%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$500,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$500,000.00**

Security

Item 26. The name of the issuer: **Catholic Health Initiatives**

Item 27. The title of the issue (including coupon or yield): **Catholic Health Initiatives 0.450000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **1491M1HN6**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Commercial Paper**

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-04**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-04**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$500,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$500,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.75%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$500,016.10**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$500,016.10**

Security

Item 26. The name of the issuer: **Chariot Funding**

Item 27. The title of the issue (including coupon or yield): **Chariot Funding 0.220000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **15963TAP4**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Asset Backed Commercial Paper**

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-01-23**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-01-23**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$420,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$419,786.96**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.47%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$419,800.08**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$419,800.08**

Security

Item 26. The name of the issuer: **Charlotte-Mecklenburg Hosp. Auth.**

Item 27. The title of the issue (including coupon or yield): **Charlotte-Mecklenburg Hosp. Auth. 0.140000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **160853MR5**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-01**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-01**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
-----------------------	--	--

Charlotte-Meck Hosp
Auth - JPM

N/A

N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$145,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$145,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.51%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$145,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$145,000.00](#)

Security

Item 26. The name of the issuer: [Colorado Housing Fin. Auth.](#)

Item 27. The title of the issue (including coupon or yield): [Colorado Housing Fin. Auth., Multi-Family 0.160000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [196479JL4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CO Housing & Fin - FHL Bank	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$835,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$835,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [2.93%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$835,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$835,000.00**

Security

Item 26. The name of the issuer: [Cuyahoga County Hosp.](#)

Item 27. The title of the issue (including coupon or yield): [Cuyahoga, Cleveland Clinic 0.130000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [232286BJ2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
County of Cuyahoga OH - U.S. BAN	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$335,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$335,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.17%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$335,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$335,000.00**

Security

Item 26. The name of the issuer: [Delaware HFA](#)

Item 27. The title of the issue (including coupon or yield): [Delaware HFA, Christiana Care 0.120000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [246388NV0](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
DE Health Fac Auth Revenue	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$370,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$370,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.30%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$370,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$370,000.00](#)

Security

Item 26. The name of the issuer: [DnB NOR Bank](#)

Item 27. The title of the issue (including coupon or yield): [DnB NOR Bank 0.370000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [2332K1Z52](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Financial Company Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-05](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-05](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$300,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$299,895.17](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.05%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$299,929.14](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$299,929.14](#)

Security

Item 26. The name of the issuer: [Export Development Canada](#)

Item 27. The title of the issue (including coupon or yield): [Export Development Canada 0.451000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [30216BBU5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Note](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-05](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-05](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$500,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$500,409.66](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.75%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$500,719.50](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$500,719.50**

Security

Item 26. The name of the issuer: [Fairway Finance](#)

Item 27. The title of the issue (including coupon or yield): [Fairway Finance 0.263000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [30601YJN6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Asset Backed Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-14](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-14](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$250,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$250,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.88%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$249,999.50**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$249,999.50**

Security

Item 26. The name of the issuer: [Federal Home Loan Mortgage](#)

Item 27. The title of the issue (including coupon or yield): [Federal Home Loan Mortgage 2.125000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [3137EACE7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Government Agency Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-09-21](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-09-21](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$254,171.55](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.89%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$254,256.74](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$254,256.74](#)

Security

Item 26. The name of the issuer: [Federal National Mortgage Assn.](#)

Item 27. The title of the issue (including coupon or yield): [Federal National Mortgage Assn. 0.200000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [313588WG6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Government Agency Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-05-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-05-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$998,988.89](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [3.50%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$999,646.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$999,646.00](#)

Security

Item 26. The name of the issuer: [Ford Credit Auto Lease Trust](#)

Item 27. The title of the issue (including coupon or yield): [Ford Credit Auto Lease Trust 0.480000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [34529TAA5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-11-15](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-11-15](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$250,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$250,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$250,000.00](#)

Security

Item 26. The name of the issuer: [GE Capital](#)

Item 27. The title of the issue (including coupon or yield): [GE Capital 3.500000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [36962G4E1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-08-13](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-08-13](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$100,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$102,246.41](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.36%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$102,143.90](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$102,143.90](#)

Security

Item 26. The name of the issuer: [GE Capital](#)

Item 27. The title of the issue (including coupon or yield): [GE Capital 0.592000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [36962GR89](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-27](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-27](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$200,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$200,223.16**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.70%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$200,151.80**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$200,151.80**

Security

Item 26. The name of the issuer: **Gregg County Health Fac. Dev. Corp.**

Item 27. The title of the issue (including coupon or yield): **Gregg County Health Fac. Dev. Corp., Good Shepherd Health 0.170000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **39753MFA1**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-01**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-01**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
Gregg Cty Health Fac Dev -TX	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JP MORGAN CHASE & CO.	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$1,050,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$1,050,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **3.68%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$1,050,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$1,050,000.00**

Security

Item 26. The name of the issuer: **Harris County Cultural Ed. Fac.**

Item 27. The title of the issue (including coupon or yield): **Harris County Cultural Ed. Fac. 0.140000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **414010AA6**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-01**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-01**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
HARRIS CTY CULTURAL EDUC FAC	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JP MORGAN CHASE & CO.	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$300,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$300,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.05%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$300,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$300,000.00**

Security

Item 26. The name of the issuer: [Harris County Health Fac. Dev. Corp.](#)

Item 27. The title of the issue (including coupon or yield): [Harris County Health Fac. Dev. Corp., Baylor College 0.140000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [414152SH2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
Harris Cty Health Fac Dev Corp	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
WELLS FARGO & COMPANY	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$210,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$210,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.74%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$210,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$210,000.00](#)

Security

Item 26. The name of the issuer: [Honda Auto Receivables Owner Trust](#)

Item 27. The title of the issue (including coupon or yield): [Honda Auto Receivables Owner Trust 0.398000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [43811AAA4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-10-22**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-10-22**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$250,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$250,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.88%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$250,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$250,000.00**

Security

Item 26. The name of the issuer: **Huntington Auto Trust**

Item 27. The title of the issue (including coupon or yield): **Huntington Auto Trust, Series 2011-1A, Class A1 0.364000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **446149AA4**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Note**

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-09-17**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-09-17**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$218,460.85**

- Item 41. The total current amortized cost, to the nearest cent: **\$218,460.85**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.77%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$218,460.84**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$218,460.84**

Security

- Item 26. The name of the issuer: **Illinois Fin. Auth.**
- Item 27. The title of the issue (including coupon or yield): **Illinois Fin. Auth. 0.200000%**
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **45203TCS3**
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Commercial Paper**
- Brief description: (optional): **[Not Provided]**
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-01-09**
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-01-09**
- Item 37. Does the security have a Demand Feature? **No**
- Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
PNC FINANCIAL SERVICES GROUP, IN	N/A	N/A

- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**
- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$400,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$400,000.00**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.40%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$399,984.00**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$399,984.00**

Security

Item 26. The name of the issuer: [Inova Health](#)

Item 27. The title of the issue (including coupon or yield): [Inova Health 0.250000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [45778NAJ3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-18](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-18](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$157,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$156,914.96](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.55%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$156,910.51](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$156,910.51](#)

Security

Item 26. The name of the issuer: [JPMorgan Chase](#)

Item 27. The title of the issue (including coupon or yield): [JPMorgan Chase, Bear Stearns 0.444000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [073902PQ5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$200,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$200,075.04](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.70%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$200,093.80](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$200,093.80](#)

Security

Item 26. The name of the issuer: [JPMorgan Chase](#)

Item 27. The title of the issue (including coupon or yield): [JPMorgan Chase 6.950000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [073928X73](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Note](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-08-10](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-08-10](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$236,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$246,843.94](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.87%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$247,246.33](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$247,246.33**

Security

Item 26. The name of the issuer: [JPMorgan Chase](#)

Item 27. The title of the issue (including coupon or yield): [JPMorgan Chase 0.388000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46623ECU1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-22](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-22](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$250,032.65](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$249,605.95](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$249,605.95](#)

Security

Item 26. The name of the issuer: [JPMorgan Chase](#)

Item 27. The title of the issue (including coupon or yield): [JPMorgan Chase, Wisconsin 0.140000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46633VHM4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPM CHASE PUTTERS - JPM CHASE	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$405,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$405,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.42%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$405,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$405,000.00](#)

Security

Item 26. The name of the issuer: [Market Street Funding](#)

Item 27. The title of the issue (including coupon or yield): [Market Street Funding 0.230000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [5705X4AK0](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Asset Backed Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-19](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-19](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$350,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$349,823.35](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.23%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$349,888.77](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$349,888.77](#)

Security

Item 26. The name of the issuer: [Maryland Economic Dev. Corp.](#)

Item 27. The title of the issue (including coupon or yield): [Maryland Economic Dev. Corp., Constellation Energy 0.130000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [574205FD7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
MARYLAND ECON DEV CORP	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
UNITED KINGDOM (GOVERNMENT OF TH	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$200,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$200,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.70%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$200,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$200,000.00**

Security

Item 26. The name of the issuer: [Maryland HHEFA](#)

Item 27. The title of the issue (including coupon or yield): [Maryland HHEFA 0.200000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57421UQP2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-10](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-10](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$139,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$139,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.49%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$138,998.61**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$138,998.61**

Security

Item 26. The name of the issuer: [Massachusetts](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts 0.130000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57582N4G7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
Massachusetts - Wells Fargo	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$100,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$100,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.35%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$100,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$100,000.00](#)

Security

Item 26. The name of the issuer: [MetLife Short Term Funding](#)

Item 27. The title of the issue (including coupon or yield): [MetLife Short Term Funding 0.450000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [59157TC50](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Asset Backed Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-03-05](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-03-05](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$300,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$299,531.25**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.05%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$299,617.80**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$299,617.80**

Security

Item 26. The name of the issuer: **Minnesota**

Item 27. The title of the issue (including coupon or yield): **Minnesota 5.000000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **604129QY5**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Municipal Debt**
Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-01**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-01**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$400,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$400,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.40%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$400,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$400,000.00**

Security

Item 26. The name of the issuer: **Mississippi Hosp. Equipment & Fac. Auth.**

Item 27. The title of the issue (including coupon or yield): [Mississippi Hosp. Equipment & Fac. Auth., North Mississippi Health 0.110000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [605360LM6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
Mississippi Hosp & Fac Auth	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$580,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$580,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [2.03%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$580,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$580,000.00](#)

Security

Item 26. The name of the issuer: [Montana Fac. Fin. Auth.](#)

Item 27. The title of the issue (including coupon or yield): [Montana Fac. Fin. Auth. 0.150000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [61204KBC4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
Montana FFA - JPMorgan	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$640,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$640,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [2.24%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$640,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$640,000.00](#)

Security

Item 26. The name of the issuer: [Montgomery County Housing Opportunities Commission](#)

Item 27. The title of the issue (including coupon or yield): [Montgomery County Housing Opportunities Commission 0.140000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [613349B65](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
Montgomery Cty Housing Comm	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$590,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$590,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **2.07%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$590,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$590,000.00**

Security

Item 26. The name of the issuer: **Morgan Stanley (FDIC TLGP)**

Item 27. The title of the issue (including coupon or yield): **Morgan Stanley (FDIC TLGP) 0.555000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **61757UAL4**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Note**

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-10**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-10**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$500,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$500,455.37**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.75%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$500,683.50**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$500,683.50**

Security

Item 26. The name of the issuer: [National Australia Bank \(New York\)](#)

Item 27. The title of the issue (including coupon or yield): [National Australia Bank \(New York\) 0.393000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [63253THM3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Certificate of Deposit](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-14](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-14](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$250,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$250,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.88%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$250,000.50**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$250,000.50**

Security

Item 26. The name of the issuer: [National Bank of Canada](#)

Item 27. The title of the issue (including coupon or yield): [National Bank of Canada 0.286000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [63306V2A7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Certificate of Deposit](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$250,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$249,949.25](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$249,949.25](#)

Security

Item 26. The name of the issuer: [Nebraska Ed. Fin. Auth.](#)

Item 27. The title of the issue (including coupon or yield): [Nebraska Ed. Fin. Auth., Creighton Univ. 0.140000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [63966PSJ4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
NEBRASKA ED FINANCE AUTH	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
-----------	--	--------------------------------

JP MORGAN CHASE & CO.

N/A

N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$210,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$210,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.74%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$210,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$210,000.00**

Security

Item 26. The name of the issuer: **New Mexico Fin. Auth.**

Item 27. The title of the issue (including coupon or yield): **New Mexico Fin. Auth. 0.180000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **64711RFT8**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
New Mexico Finance Authority	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
ROYAL BANK OF CANADA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$200,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$200,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.70%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$200,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$200,000.00](#)

Security

Item 26. The name of the issuer: [New York City](#)

Item 27. The title of the issue (including coupon or yield): [New York City 0.110000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [64966FA87](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
City of New York NY	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF NEW YORK MELLON CORP	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$370,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$370,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.30%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$370,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$370,000.00](#)

Security

Item 26. The name of the issuer: [New York Life Global Funding](#)

Item 27. The title of the issue (including coupon or yield): [New York Life Global Funding 0.395000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [64952WBD4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Instrument](#)
 Brief description: (optional): [Short MTN/Promissory Note](#)

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-29](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-29](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$250,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$249,984.50](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$249,984.50](#)

Security

Item 26. The name of the issuer: [New York State Housing Fin. Agency](#)

Item 27. The title of the issue (including coupon or yield): [New York State Housing Fin. Agency, 600 West 42nd 0.210000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [64986MT70](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)
 Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
New York State Housing Fin Ag	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF NEW YORK MELLON CORP	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$100,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$100,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.35%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$100,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$100,000.00](#)

Security

Item 26. The name of the issuer: [New York State Housing Fin. Agency](#)

Item 27. The title of the issue (including coupon or yield): [New York State Housing Fin. Agency 4.510000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [649870DC3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-03-15](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-03-15](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$120,000.00](#)

- Item 41. The total current amortized cost, to the nearest cent: [\\$121,661.88](#)
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.43%](#)
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$121,687.20](#)
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$121,687.20](#)

Security

- Item 26. The name of the issuer: [New York State Liberty Dev. Corp.](#)
- Item 27. The title of the issue (including coupon or yield): [New York State Liberty Dev. Corp. 0.330000%](#)
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [649519BH7](#)
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-05-08](#)
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-05-08](#)
- Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
NEW YORK LIBERTY DEV CORP	N/A	N/A

- Item 38. Does the security have a Guarantee? [No](#)
- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
- Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)
- Item 41. The total current amortized cost, to the nearest cent: [\\$250,000.00](#)
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$250,002.50](#)
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$250,002.50](#)

Security

- Item 26. The name of the issuer: [New York State Urban Dev. Corp.](#)

Item 27. The title of the issue (including coupon or yield): [New York State Urban Dev. Corp. 1.315000%](#)
 Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [650035TA6](#)
 Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
 Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
 Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
 Brief description: (optional): [Not Provided]
 Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
 Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
 Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-15](#)
 Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-15](#)
 Item 37. Does the security have a Demand Feature? [No](#)
 Item 38. Does the security have a Guarantee? [No](#)
 Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
 Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)
 Item 41. The total current amortized cost, to the nearest cent: [\\$250,264.79](#)
 Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)
 Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
 Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
 Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$250,367.50](#)
 Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$250,367.50](#)

Security

Item 26. The name of the issuer: [North Carolina Medical Care Commission](#)
 Item 27. The title of the issue (including coupon or yield): [North Carolina Medical Care Commission Retirement Fac., WakeMed 0.130000%](#)
 Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [65821DCW9](#)
 Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
 Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
 Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)
 Brief description: (optional): [Not Provided]
 Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
 Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
 Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
NC Med Care Comm Retirem Facs	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
WELLS FARGO & COMPANY	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$325,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$325,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.14%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$325,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$325,000.00](#)

Security

Item 26. The name of the issuer: [Old Line Funding](#)

Item 27. The title of the issue (including coupon or yield): [Old Line Funding 0.220000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [67983UZ89](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Asset Backed Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-08](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-08](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$371,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$370,916.11**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.30%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$370,960.82**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$370,960.82**

Security

- Item 26. The name of the issuer: **Principal Life Global Funding I**
- Item 27. The title of the issue (including coupon or yield): **Principal Life Global Funding I 0.569000%**
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **7425A0BH2**
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Insurance Company Funding Agreement**
- Brief description: (optional): **[Not Provided]**
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-30**
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-30**
- Item 37. Does the security have a Demand Feature? **No**
- Item 38. Does the security have a Guarantee? **No**
- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**
- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$250,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$250,000.00**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.88%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$249,961.50**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$249,961.50**

Security

- Item 26. The name of the issuer: **Providence Health & Services**
- Item 27. The title of the issue (including coupon or yield): **Providence Health & Services 0.400000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [74375WEE7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-08](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-08](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$375,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$375,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.31%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$375,058.76](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$375,058.76](#)

Security

Item 26. The name of the issuer: [Rabobank Nederland](#)

Item 27. The title of the issue (including coupon or yield): [Rabobank Nederland 0.340000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [74977MUM5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Certificate of Deposit](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-25](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-25](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$250,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$249,941.25](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$249,941.25](#)

Security

Item 26. The name of the issuer: [Reckitt Benckiser Treasury](#)

Item 27. The title of the issue (including coupon or yield): [Reckitt Benckiser Treasury 0.720000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [7562E0C87](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-03-08](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-03-08](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$249,360.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.87%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$249,608.53](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$249,608.53](#)

Security

Item 26. The name of the issuer: [Reckitt Benckiser Treasury](#)

Item 27. The title of the issue (including coupon or yield): [Reckitt Benckiser Treasury 0.550000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [7562E1ZL1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-20](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-20](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$249,812.85](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$249,903.83](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$249,903.83](#)

Security

Item 26. The name of the issuer: [Regional Transportation Auth.](#)

Item 27. The title of the issue (including coupon or yield): [Regional Transportation Auth. 0.270000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [75914UAN0](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

N/A

N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-05](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-05](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JP MORGAN CHASE & CO.	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$350,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$350,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.23%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$350,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$350,000.00](#)

Security

Item 26. The name of the issuer: [Royal Bank of Canada](#)

Item 27. The title of the issue (including coupon or yield): [Royal Bank of Canada 0.470000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [78009NAB2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Certificate of Deposit](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

N/A

N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$250,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$249,898.75](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$249,898.75](#)

Security

Item 26. The name of the issuer: [Rutgers Univ.](#)

Item 27. The title of the issue (including coupon or yield): [Rutgers State Univ. 0.320000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [78318GBW6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-06](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-06](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$197,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$197,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.69%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$197,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$197,000.00](#)

Security

Item 26. The name of the issuer: [Rutgers Univ.](#)

Item 27. The title of the issue (including coupon or yield): [Rutgers State Univ. 0.260000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [78318GCB1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-03](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-03](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$240,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$240,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.84%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$240,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$240,000.00](#)

Security

Item 26. The name of the issuer: [San Jose](#)

Item 27. The title of the issue (including coupon or yield): [San Jose 0.260000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [79817SAX3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-03](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-03](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
WELLS FARGO & COMPANY	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$359,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$359,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.26%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$359,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$359,000.00**

Security

Item 26. The name of the issuer: **Shell International Finance**

Item 27. The title of the issue (including coupon or yield): **Shell International Finance 0.705000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **822582AP7**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Note**

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-12-22**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-12-22**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$250,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$250,675.24**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.88%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$250,678.25**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$250,678.25**

Security

Item 26. The name of the issuer: [Siemens Capital](#)

Item 27. The title of the issue (including coupon or yield): [Siemens Capital 0.160000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [82619UJK3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-19](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-19](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$344,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$343,926.61](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.21%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$343,871.24](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$343,871.24](#)

Security

Item 26. The name of the issuer: [Southern Ute Indian Tribe](#)

Item 27. The title of the issue (including coupon or yield): [Southern Ute Indian Tribe 0.250000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [844090AB6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
Southern Ute Indian Tribe - CO	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$560,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$560,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.96%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$560,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$560,000.00](#)

Security

Item 26. The name of the issuer: [Standard Chartered Bank](#)

Item 27. The title of the issue (including coupon or yield): [Standard Chartered Bank 0.640000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [85324TAL0](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Financial Company Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-20](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-20](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$260,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$259,630.22**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.91%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$259,805.78**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$259,805.78**

Security

Item 26. The name of the issuer: **Straight-A Funding**

Item 27. The title of the issue (including coupon or yield): **Straight-A Funding 0.180000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **86257FBE4**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Asset Backed Commercial Paper**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-12-28**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-12-28**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$718,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$717,795.37**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **2.52%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$717,942.13**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$717,942.13**

Security

Item 26. The name of the issuer: **Straight-A Funding**

Item 27. The title of the issue (including coupon or yield): [Straight-A Funding 0.190000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [86257M2S8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Asset Backed Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-28](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-28](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$330,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$329,952.98](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.16%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$329,971.75](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$329,971.75](#)

Security

Item 26. The name of the issuer: [Sumitomo Mitsui Banking](#)

Item 27. The title of the issue (including coupon or yield): [Sumitomo Mitsui Banking 0.325000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [86562LZF2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Financial Company Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-15](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-15](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$400,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$399,841.11](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.40%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$399,865.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$399,865.00](#)

Security

Item 26. The name of the issuer: [Tarrant County Cultural Ed. Fac. Fin. Corp.](#)

Item 27. The title of the issue (including coupon or yield): [Tarrant County Cultural Ed. Fac. Fin. Corp., Texas Health Resources 0.130000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [87638TCG6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
Tarrant Cty Cult Ed Fac Fin	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$315,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$315,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.10%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$315,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$315,000.00**

Security

Item 26. The name of the issuer: **Tarrant County Cultural Ed. Fac. Fin. Corp.**

Item 27. The title of the issue (including coupon or yield): **Tarrant County Cultural Ed. Fac. Fin. Corp., Texas Health Resources 0.130000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **87638TCJO**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-01**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-01**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
Tarrant Cty Fac Fin - JPMChase	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$410,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$410,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.44%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$410,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$410,000.00**

Security

Item 26. The name of the issuer: **Tennessee**

Item 27. The title of the issue (including coupon or yield): **Tennessee 0.320000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [88055PHY2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-04](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-04](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$250,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$250,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$250,000.00](#)

Security

Item 26. The name of the issuer: [Texas](#)

Item 27. The title of the issue (including coupon or yield): [Texas, Veterans Land 0.200000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [8827202R5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
Texas - STATE STREET CORP	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$685,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$685,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [2.40%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$685,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$685,000.00](#)

Security

Item 26. The name of the issuer: [Toronto-Dominion Bank](#)

Item 27. The title of the issue (including coupon or yield): [Toronto-Dominion Bank 0.263000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [89112YC68](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Certificate of Deposit](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-14](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-14](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$250,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$249,957.75](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$249,957.75](#)

Security

Item 26. The name of the issuer: [Univ. of California](#)

Item 27. The title of the issue (including coupon or yield): [Univ. of California 0.250000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [91411SB66](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-02-06](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-02-06](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$450,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$449,696.88](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.58%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$449,694.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$449,694.00](#)

Security

Item 26. The name of the issuer: [Variable Funding Capital](#)

Item 27. The title of the issue (including coupon or yield): [Variable Funding Capital 0.250000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [92217LAH2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Asset Backed Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-01-17**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-01-17**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$400,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$399,786.11**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.40%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$399,759.08**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$399,759.08**

Security

Item 26. The name of the issuer: **Virginia College Building Auth.**

Item 27. The title of the issue (including coupon or yield): **Virginia College Building Auth. 0.140000%**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **927781CQ5**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-01**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-01**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
Virginia CBA - Wells Fargo	N/A	N/A

- Item 38. Does the security have a Guarantee? [No](#)
- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
- Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$500,000.00](#)
- Item 41. The total current amortized cost, to the nearest cent: [\\$500,000.00](#)
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.75%](#)
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$500,000.00](#)
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$500,000.00](#)

Security

- Item 26. The name of the issuer: [Westpac Banking](#)
- Item 27. The title of the issue (including coupon or yield): [Westpac Banking 0.343000%](#)
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [96121TFF0](#)
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Certificate of Deposit](#)
Brief description: (optional): [Not Provided]
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-17](#)
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-17](#)
- Item 37. Does the security have a Demand Feature? [No](#)
- Item 38. Does the security have a Guarantee? [No](#)
- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
- Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$150,000.00](#)
- Item 41. The total current amortized cost, to the nearest cent: [\\$149,968.01](#)
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.53%](#)
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$149,889.30](#)
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$149,889.30](#)

Security

- Item 26. The name of the issuer: [Westpac Securities](#)

Item 27. The title of the issue (including coupon or yield): [Westpac Securities 0.458000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [96122JBD0](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Financial Company Commercial Paper](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-09-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-09-07](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$250,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.88%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$249,997.50](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$249,997.50](#)

Security

Item 26. The name of the issuer: [Wisconsin Housing & Economic Dev. Auth.](#)

Item 27. The title of the issue (including coupon or yield): [Wisconsin Housing & Economic Dev. Auth., Home Ownership 0.270000%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [97689PP93](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
N/A	N/A

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
WI HDA - FED HOME LOAN BANK	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$830,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$830,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [2.91%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$830,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$830,000.00](#)